On November 13, 2024, OneSkin, a biotech skin health brand, announced the successful completion of an oversubscribed Series A financing led by Selva Ventures, with participation from PLUS Capital, Unilever Ventures, Able Partners, and former investors SOSV, Meta Planet, and additional investors. The latest round brings the total company funding to $20 million. Wilson Sonsini Goodrich & Rosati advised OneSkin on intellectual property matters related to the transaction and has advised the company on IP matters generally since its founding in 2016.

OneSkin—an IndieBio company—has been recognized as a market leader in scientific, topical skin longevity treatments since its launch.  The company's patented OS-01 peptide has been scientifically proven to target the root cause of aging skin, and with its proprietary formulations helps improve fine lines and wrinkles. The additional capital will be used to bolster research and development and accelerate growth plans.

The Wilson Sonsini team advising OneSkin on the transaction includes Maya Skubatch, Lori Westin, Ellie Han, and Nicole Zeinstra.

For more information, please see OneSkin's news release. Additional coverage can be found on IndieBio.